Gland Pharma
- All
- News
-
5 Consistent Compounding Stocks Available at Discount. Time to Buy?
The good side of a market correction? Investors get consistent compounding stocks at a discount.
-
5 Indian Stocks That Pass The Peter Lynch Filter
Long-term investing is an age-old investing practice that requires investors to invest with a long-term horizon, for example more than 7 years.
-
India's Gland Pharma To Produce Up To 252 Million Doses For Russia's Sputnik V Vaccine
India's Gland Pharma Ltd said on Tuesday it has entered into an agreement with the Russian Direct Investment Fund (RDIF) to produce and supply up to 252 million doses of the Sputnik V COVID-19 vaccine.
-
Gland Pharma Rallies On Agreement To Produce Sputnik V Covid-19 Vaccine
Gland Pharma has entered into an agreement to produce and supply 252 million doses of RDIF Sputnik V COVID-19 vaccine.
-
Gland Pharma Shares Make Strong Market Debut, Lists At A Premium Of 13%
Gland Pharma debut today: Gland Pharma share rises to as much as Rs 1,850 on the BSE, up by 23 per cent as compared to issue price of Rs 1,500.
-
Gland Pharma To Debut On BSE, NSE On Friday
Gland Pharma's Rs 6,480 crore initial public offering (IPO) had received a muted response; It was subscribed by a mere 2.06 per cent, receiving bids for 6,21,55,670 shares as against the issue size of 3,02,37,879 shares.
-
Gland Pharma IPO: Here's How To Check Allotment Status
China's Fosun Pharma-backed Gland Pharma's Rs 6,480 crore IPO had managed to sail through, bagging subscription of a mere 2.06 per cent.
-
Gland Pharma IPO Oversubscribed On Final Day Of Subscription
Gland Pharma's public offer will be the largest pharma IPO in the country, as per estimates. It will also be the Indian company, with Chinese parentage, to tap the primary marker for funding.
-
Gland Pharma IPO Subscribed 22% On Second Day Of Subscription
Gland Pharma's public offer will be the largest pharma IPO in the country, as per estimates. It will also be the Indian company, with Chinese parentage, to tap the primary marker for funding.
-
Gland Pharma IPO Opens For Subscription. Here's All You Need To Know
Gland Pharma IPO: The offer consists of a fresh issue of shares worth around Rs 1,250 crore and an offer for sale of more than 3.4 crore shares by Fosun Pharma, Gland Celsus Bio Chemicals, Empower Discretionary Trust and Nilay Discretionary Trust.
-
Gland Pharma Garners Rs 1,944 Crore From Anchor Investors Prior To IPO
The anchor investors include Government of Singapore, Nomura, Goldman Sachs, Morgan Stanley, SBI Mutual Fund, Axis Mutual Fund and SBI Life Insurance and Fidelity.
-
Gland Pharma IPO To Open On November 9, Price Fixed At Rs 1,490-1,500 A Share
The public issue will be open for three days, from November 9 to November 11, and the shares will be offered in the price band at Rs 1,490-1,500 per share.
-
Gland Pharma Gets Nod To Float IPO
The IPO comprises fresh issue of shares amounting to up to Rs 1,250 crore and an offer for sale of more than 3.4 crore shares, draft papers filed with SEBI reveal.
-
Fosun Pharma Completes Largest Ever Chinese Acquisition In India For $1.09 Billion
The Chinese firm decided to scale down its proposed acquisition in Gland Pharma to 74% following objections by government bodies.
-
China's Fosun Pharma To Buy Smaller Stake In Indian Firm
Fosun had previously sought an 86 percent stake in what is set to be China's biggest acquisition in India.
-
5 Consistent Compounding Stocks Available at Discount. Time to Buy?
The good side of a market correction? Investors get consistent compounding stocks at a discount.
-
5 Indian Stocks That Pass The Peter Lynch Filter
Long-term investing is an age-old investing practice that requires investors to invest with a long-term horizon, for example more than 7 years.
-
India's Gland Pharma To Produce Up To 252 Million Doses For Russia's Sputnik V Vaccine
India's Gland Pharma Ltd said on Tuesday it has entered into an agreement with the Russian Direct Investment Fund (RDIF) to produce and supply up to 252 million doses of the Sputnik V COVID-19 vaccine.
-
Gland Pharma Rallies On Agreement To Produce Sputnik V Covid-19 Vaccine
Gland Pharma has entered into an agreement to produce and supply 252 million doses of RDIF Sputnik V COVID-19 vaccine.
-
Gland Pharma Shares Make Strong Market Debut, Lists At A Premium Of 13%
Gland Pharma debut today: Gland Pharma share rises to as much as Rs 1,850 on the BSE, up by 23 per cent as compared to issue price of Rs 1,500.
-
Gland Pharma To Debut On BSE, NSE On Friday
Gland Pharma's Rs 6,480 crore initial public offering (IPO) had received a muted response; It was subscribed by a mere 2.06 per cent, receiving bids for 6,21,55,670 shares as against the issue size of 3,02,37,879 shares.
-
Gland Pharma IPO: Here's How To Check Allotment Status
China's Fosun Pharma-backed Gland Pharma's Rs 6,480 crore IPO had managed to sail through, bagging subscription of a mere 2.06 per cent.
-
Gland Pharma IPO Oversubscribed On Final Day Of Subscription
Gland Pharma's public offer will be the largest pharma IPO in the country, as per estimates. It will also be the Indian company, with Chinese parentage, to tap the primary marker for funding.
-
Gland Pharma IPO Subscribed 22% On Second Day Of Subscription
Gland Pharma's public offer will be the largest pharma IPO in the country, as per estimates. It will also be the Indian company, with Chinese parentage, to tap the primary marker for funding.
-
Gland Pharma IPO Opens For Subscription. Here's All You Need To Know
Gland Pharma IPO: The offer consists of a fresh issue of shares worth around Rs 1,250 crore and an offer for sale of more than 3.4 crore shares by Fosun Pharma, Gland Celsus Bio Chemicals, Empower Discretionary Trust and Nilay Discretionary Trust.
-
Gland Pharma Garners Rs 1,944 Crore From Anchor Investors Prior To IPO
The anchor investors include Government of Singapore, Nomura, Goldman Sachs, Morgan Stanley, SBI Mutual Fund, Axis Mutual Fund and SBI Life Insurance and Fidelity.
-
Gland Pharma IPO To Open On November 9, Price Fixed At Rs 1,490-1,500 A Share
The public issue will be open for three days, from November 9 to November 11, and the shares will be offered in the price band at Rs 1,490-1,500 per share.
-
Gland Pharma Gets Nod To Float IPO
The IPO comprises fresh issue of shares amounting to up to Rs 1,250 crore and an offer for sale of more than 3.4 crore shares, draft papers filed with SEBI reveal.
-
Fosun Pharma Completes Largest Ever Chinese Acquisition In India For $1.09 Billion
The Chinese firm decided to scale down its proposed acquisition in Gland Pharma to 74% following objections by government bodies.
-
China's Fosun Pharma To Buy Smaller Stake In Indian Firm
Fosun had previously sought an 86 percent stake in what is set to be China's biggest acquisition in India.
